CSJA:FRA
CSL ADR
၂၉.၈၀ €
arrow_downward
-၀.၆၇%(-၀.၂၀) 1D
အောက် ၂၁, GMT+၂ ၂၂:၀၀:၀၀ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CSJA...
Open
၂၈.၈၀ €
High
၂၉.၈၀ €
Low
၂၈.၈၀ €
Mkt. cap
ဋေ ၉.၄၁ ထ
Avg. vol.
၁၀.၀၀
Volume
၀.၀၀
52-wk high
၄၃.၄၀ €
52-wk low
၁၂.၇၀ €
No. of employees
၃ သောင်း
Open
၂၈.၈၀ €
High
၂၉.၈၀ €
Low
၂၈.၈၀ €
Mkt. cap
ဋေ ၉.၄၁ ထ
Avg. vol.
၁၀.၀၀
Volume
၀.၀၀
52-wk high
၄၃.၄၀ €
52-wk low
၁၂.၇၀ €
No. of employees
၃ သောင်း
News stories
From web sources and news partners
Fierce Pharma
·
ပြီးခဲ့သည့် ၆ နာရီ
CSL taps GSK’s Deborah Waterhouse as CEO in the darkest hour
Pharmaceutical Executive
·
ပြီးခဲ့သည့် ၇ နာရီ
CSL Names Deborah Waterhouse as CEO and Manager Director
Investing.com
·
ပြီးခဲ့သည့် ၁၁ နာရီ
CSL names Deborah Waterhouse as new chief executive
Stock Titan
·
ပြီးခဲ့သည့် ၁၂ နာရီ
A GSK-majority-owned HIV medicines company had £7.7B in sales in GSK's 2025 financial year. Its CEO will lead CSL.
Profile
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
About CSL ADR
CEOPaul McKenzie
Employees၂.၉ သောင်း
Founded၁၉၁၆
Headquartersမဲလ်ဘုန်းမြို့, ဝိတိုရိယ ပြည်နယ်, ဩစတြေးလျ
Sector-
Websitecsl.com